Learn the important cardio-renal benefits that SGLT2 inhibitors can bring to improve overall health outcomes.
This educational post explores one of the most clinically significant classes of medications in modern medicine: sodium-glucose cotransporter-2 (SGLT2) inhibitors. As a practitioner who bridges chiropractic care, functional medicine, and advanced nursing practice, I present the latest evidence-based findings on how SGLT2 inhibitors work, who benefits most from them, and why they represent a paradigm shift in managing the interconnected conditions of type 2 diabetes (T2DM), chronic kidney disease (CKD), and heart failure (HF). We will examine the physiological underpinnings of cardiorenal complications, landmark clinical trials, and updated clinical guidelines, all viewed through the integrative, multidisciplinary lens of Injury Medical Clinic PA in El Paso, Texas. I will draw on the foundational clinical narrative of Dr. Elijah David Solomon, DNP, CDCES, FNP, and a detailed case study to illustrate how this pharmacological knowledge integrates into the broader multidisciplinary model where medical oversight from Dr. Maria Guadalupe Cardenas, MD, and integrative chiropractic and functional medicine care converge to deliver comprehensive patient outcomes.
When I reflect on the journey that leads any clinician into a specialized field, it is rarely just academic. For many of us, it is deeply personal. I have followed the clinical narrative of Dr. Elijah David Solomon, DNP, CDCES, FNP, with great attention, because his story mirrors a truth I have witnessed repeatedly in my own practice: diabetes is not just a laboratory number — it is a lived experience with profound physiological, neurological, and vascular consequences.
Dr. Solomon shared that as a Filipino child, he was assigned to watch over his grandmother, who was a stroke survivor with what he later understood to be poorly managed diabetes. During one night of caregiving, while applying topical analgesic to her legs — her remedy for everything — he discovered not sand on her skin, but ants. His grandmother’s legs, neuropathic and ulcerated from chronic hyperglycemia, had attracted insects feeding on glucose-laden, poorly perfused tissue. This is one of the most viscerally accurate portrayals of diabetic peripheral neuropathy and lower extremity vascular compromise I have encountered outside of a clinical journal.
This is the reality of what chronic, unmanaged Type 2 Diabetes Mellitus (T2DM) produces at the tissue level. Hyperglycemia drives the formation of advanced glycation end-products (AGEs), oxidative stress, endothelial dysfunction, and small-vessel disease. The result is peripheral neuropathy, impaired wound healing, increased susceptibility to infection, and ultimately the devastating sequelae of cardiovascular and renal disease. Dr. Solomon’s early observation — that food intake, medication adherence, and blood glucose monitoring could meaningfully alter these outcomes — laid the foundation for an evidence-based career in diabetes education and care.
Before diving into the clinical content, it is important to understand the care model from which this education emerges. At Injury Medical Clinic PA — also known as Mission Plaza Injury Medical Clinic — located in El Paso, Texas, our clinical model is built on the premise that no single discipline can comprehensively address the complexity of chronic metabolic disease, musculoskeletal injury, or neurological compromise on its own.
I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, and my practice is anchored in the integration of chiropractic care, functional medicine, advanced practice nursing, and injury rehabilitation. My clinical observations and patient care philosophies are documented on personalinjurydoctorgroup.com and in my professional profile on LinkedIn.
Serving as our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933), who is Board Certified in Internal Medicine with over 40 years of experience as an internist. Dr. Cardenas brings an extraordinary depth of clinical knowledge in managing systemic diseases — including cardiovascular disease, renal dysfunction, hypertension, and metabolic syndrome — all of which intersect directly with SGLT2 inhibitor therapy.
This multidisciplinary structure is purposefully designed and is increasingly recognized as a gold standard in integrative and injury care clinics. It allows for a deliberately structured, multidisciplinary integrative care model where:
This setup ensures that when a patient presents with type 2 diabetes, CKD, or cardiovascular disease, they receive coordinated care that addresses inflammation, physical function, metabolic health, and systemic disease simultaneously (Jimenez, 2024).
To appreciate why SGLT2 inhibitors have become so transformational, we must first step back and grasp the sheer scale of the conditions they treat. Data spanning 1990 to 2017 — which, as of June 2026, is now nearly nine years old, meaning current figures are almost certainly higher — paints a sobering picture.
These numbers represent not just financial strain but also an enormous human cost, measured by a metric called the DALY (Disability-Adjusted Life Year). One DALY equals the loss of one full year of healthy life due to premature death or disability. The global burden of CKD accounts for 35.8 million DALYs — meaning 35.8 million years of healthy human life were lost.
The DALY burden of heart failure was broken down across three categories:
These statistics are not abstract numbers. They represent families, communities, and systems overwhelmed by preventable disease progression. This is precisely why optimizing treatment at the intersection of these conditions is one of the most urgent priorities in modern clinical medicine (GBD Chronic Kidney Disease Collaboration, 2020).
When we reintroduce diabetes into the equation, a powerful convergence emerges. Type 2 diabetes, CKD, and heart failure do not simply coexist — they amplify one another in a destructive physiological loop. Whether the relationship is causative or correlational, the clinical overlap is undeniable.
As of 2020, 38.4 million adults in the United States had type 2 diabetes. Of those, 20 to 40 percent — roughly 7 to 15 million people — had associated CKD with declining kidney function. For these patients, progression toward heart failure and major cardiovascular events is not a possibility; it is a trajectory without intervention.
I have seen this firsthand since my days in NP school, when I logged clinical cases. Every time I entered a diabetes diagnosis code, it was almost reflexively followed by hypertension, hyperlipidemia, CKD, or heart failure. What I knew in theory was confirmed case after case in clinical practice. The midpoint of these three overlapping conditions — where diabetes, CKD, and heart failure intersect simultaneously — is not simply a medical challenge. It is the greatest opportunity for optimizing treatment.
Understanding why these conditions spiral together requires a solid grasp of physiology. I explain it to my patients using a straightforward analogy that makes the science tangible.
Imagine honey or syrup. When a liquid is very sweet, it becomes viscous, sticky, and slow-moving. Now imagine that same thick, syrupy consistency circulating through your blood vessels. The heart must work considerably harder to propel that dense, high-glucose blood through the circulatory system. This is not a metaphor — it is a literal increase in cardiac workload driven by elevated blood viscosity and changes in osmotic pressure.
Now think about what sugar does to soft tissue. Keep hard candy against the inside of your cheek for even one hour. That tissue hardens. Sugar is profoundly inflammatory, and elevated blood glucose causes structural changes throughout every vessel it touches — hardening arterial walls, damaging the delicate filtration membranes of the kidneys, and triggering inflammatory cascades that erode cardiovascular and renal integrity over time.
The full cardiorenal mechanism unfolds as follows:
This is the vicious cardiorenal cycle. Two ends close simultaneously: elevated glucose directly stresses the heart, while impaired kidney function increases fluid retention and RAAS activation — both attacking the heart from different directions (Heerspink et al., 2020).
Sodium-Glucose Cotransporter-2 (SGLT2) is a protein expressed primarily in the proximal convoluted tubule of the kidney. Under normal physiological conditions, SGLT2 reabsorbs approximately 90% of filtered glucose back into the circulation. This mechanism evolved to prevent glucose loss during fasting and metabolic stress. However, in the context of chronic hyperglycemia, this reabsorption becomes pathological — the kidney continuously reclaims glucose that the body cannot effectively utilize, perpetuating the hyperglycemic state.
SGLT2 inhibitors — including agents such as empagliflozin, dapagliflozin, and canagliflozin — work by blocking SGLT2 receptors, forcing the kidney to excrete glucose in the urine (glucosuria). This mechanism:
SGLT2 inhibitors also produce a modest but clinically meaningful reduction in intraglomerular pressure — the pressure within the kidney’s filtration units. Elevated intraglomerular pressure stretches the glomerular filtration membrane, widening the “mesh” of the filter and allowing larger molecules — particularly albumin and other proteins — to spill into the urine. This is microalbuminuria, one of the earliest and most concerning markers of kidney damage.
By reducing intraglomerular pressure, SGLT2 inhibitors reduce proteinuria, directly protecting renal architecture. This mechanism is one of the most important teaching points I use with patients to help them understand that this medication does far more than lower blood sugar — it actively shields the kidneys from ongoing structural damage.
SGLT2 inhibitors have earned a broad and expanding set of FDA-approved indications, reflecting their multisystem benefits:
Off-label and emerging uses include:
Sick day management is a critical teaching point. When a patient is acutely ill — febrile, septic, or hemodynamically compromised — and not eating adequately, the substrate shift promoted by SGLT2 inhibitors can drive ketone production and DKA. Patients should be counseled to hold the medication during acute illness.
Perioperative management carries similar risk. Fasting states combined with surgical stress can precipitate DKA in patients maintained on SGLT2 inhibitors. Standard protocols now recommend holding the medication 3 to 4 days before elective surgery.
Genitourinary infections are among the most commonly discussed side effects. By concentrating glucose in the urine, SGLT2 inhibitors create a substrate-rich environment for urogenital yeast infections (candidiasis) and urinary tract infections (UTIs). I make adequate hydration a non-negotiable teaching point when initiating these agents.
Foot infections deserve special attention. Although an earlier FDA boxed warning related to lower-limb amputation risk has been revisited, in my clinical observation — consistent with feedback from podiatry colleagues — patients on SGLT2 inhibitors who develop active foot infections appear to experience delayed wound healing. I continue to temporarily hold SGLT2 inhibitors in patients with complicated foot infections until the infection resolves.
Ketogenic diet combinations present a nuanced but serious risk. Patients who dramatically restrict carbohydrate intake while on SGLT2 inhibitors create a state where the drug has minimal glucose to excrete. The body compensates by using substrates — breaking down fat to generate glucose, which simultaneously releases ketones. This can precipitate euglycemic DKA, even when blood sugar appears normal. Patients should be counseled explicitly about this risk.
The cardiorenal benefits of SGLT2 inhibitors have been confirmed in numerous landmark outcomes trials, demonstrating statistically significant reductions in major adverse cardiovascular events (MACE), hospitalization for heart failure, and progression of CKD.
Three pivotal trials demonstrating cardiovascular protection include:
| Trial | Agent | N | MACE Relative Risk Reduction | HF Hospitalization RRR |
| EMPA-REG OUTCOME | Empagliflozin (Jardiance) | 7,020 | 30%+ | 35% |
| VERTIS CV | Ertugliflozin | 8,246 | 12% | 30% |
| CREDENCE | Canagliflozin (Invokana) | 4,401 | 30%+ | 39% |
Both empagliflozin and canagliflozin demonstrated more than 30% relative risk reductions in MACE, while all three agents showed meaningful reductions in heart failure hospitalization (Perkovic et al., 2019; Zinman et al., 2015).
Three additional trials focused specifically on kidney protection:
| Trial | Agent | Primary Outcome | Relative Risk Reduction |
| CREDENCE | Canagliflozin | ESRD, creatinine doubling, renal/CV death | 30% |
| DAPA-CKD | Dapagliflozin | ESRD, creatinine doubling, renal/CV death | 39% |
| EMPA-KIDNEY | Empagliflozin | ESRD, creatinine doubling, renal/CV death | 28% |
Across both cardiovascular and renal domains, the consistency of benefit observed with multiple SGLT2 inhibitor agents and across diverse patient populations is striking (Heerspink et al., 2020; The EMPA-KIDNEY Collaborative Group, 2022).
The American Diabetes Association (ADA) is unambiguous: in adults with type 2 diabetes who have established atherosclerotic cardiovascular disease (ASCVD) or are at high risk for ASCVD, treatment should include agents with demonstrated cardiovascular benefit — specifically GLP-1 receptor agonists and/or SGLT2 inhibitors — irrespective of A1C level. The same recommendation applies to patients with CKD and a confirmed eGFR of 20–60 mL/min/1.73 m² or significant albuminuria: SGLT2 inhibitors should be prioritized for both glycemic management and slowing CKD progression, again independent of glycemic control (American Diabetes Association, 2025).
The American Association of Clinical Endocrinology (AACE) echoes this precisely. For patients with established ASCVD or at high risk for ASCVD, heart failure, and/or CKD, clinicians should prescribe a GLP-1 receptor agonist or SGLT2 inhibitor with proven efficacy for the specific condition, regardless of glycemic control (Blonde et al., 2022).
The message from both guidelines is consistent and clear: SGLT2 inhibitors have graduated beyond glucose-lowering agents. They are cardioprotective and nephroprotective therapies that also happen to lower blood sugar.
To illustrate these concepts in a real-world scenario, let me introduce you to a patient we’ll call R.B. He is a 68-year-old Hispanic male with a 15-year history of type 2 diabetes, complicated by hypertension, hyperlipidemia, and emerging chronic kidney disease.
When he first came to my office on June 2, 2026, his health was at a critical juncture. Despite a medication list that included Glargine (Lantus) insulin, glipizide, linagliptin, losartan, hydrochlorothiazide, and simvastatin, his health was deteriorating. His A1C was a dangerously high 10.2%. His kidney function was declining, with an estimated glomerular filtration rate (eGFR) of 43 mL/min. His daily blood sugar readings averaged 200-300 mg/dL, followed by frightening hypoglycemic episodes at night.
This patient exemplifies the ties that bind in real life. His overlapping diagnoses placed him at high risk for MACE, progressive CKD, and heart failure hospitalization. My priority was not to add another pill but to empower him with knowledge. We discovered a vicious cycle: fear of nighttime lows led to preemptive eating, which caused daytime hyperglycemia, which prompted higher insulin doses, which in turn caused the nighttime lows.
To break the cycle, we immediately discontinued glipizide and educated him about nutrition and mealtime insulin. One of the most significant breakthroughs was addressing his fear of a continuous glucose monitor (CGM). A simple hands-on demonstration of a demo unit dispelled his misconception about a large needle and opened the door to 24/7 glucose data.
Two weeks later, on June 16, 2026, his blood sugars had improved, and his lows had stopped. Lab work confirmed he was still producing his own insulin, making it safe to introduce dapagliflozin (Farxiga), an SGLT2 inhibitor.
Three months later, on September 16, 2026, the results were stunning: his A1C dropped to 8.2,% and his eGFR improved from 43 to 53 mL/min. His kidney function was actively improving. We then switched him to semaglutide (Ozempic), a GLP-1 receptor agonist with proven cardiovascular benefits, to further optimize his regimen.
By his seven-month follow-up on January 16, 2027R.B.’s’s transformation was remarkable. His A1C dropped further to 7.2%, and his eGFR increased to 55 mL/min. Most impressively, he was achieving this without needing mealtime insulin. The SGLT2 inhibitor and GLP-1 RA were working synergistically to provide excellent glycemic control. His journey is a testament to the fact that a modern, holistic approach can truly transform lives.
While SGLT2 inhibitors represent a powerful pharmacological tool, they are most effective when embedded within a comprehensive, multidisciplinary treatment strategy. This is where the integrative model at Injury Medical Clinic PA becomes particularly valuable. Patients with Type 2 Diabetes, Chronic Kidney Disease (CKD), and Heart Failure (HF) often present with overlapping musculoskeletal dysfunction, including:
Each of these conditions creates a feedback loop that worsens glycemic control and accelerates cardiorenal decline. Chiropractic care, as practiced within our integrative model, addresses the neuromusculoskeletal contributions to this cascade. Spinal manipulation and mobilization reduce nociceptive input that drives sympathetic nervous system hyperactivation — a mechanism directly linked to insulin resistance and hypertension (Kovanur Sampath et al., 2017). When the autonomic nervous system is dysregulated, cortisol and catecholamine output rise, impairing glucose metabolism and increasing cardiovascular load. By restoring spinal biomechanics and neuromuscular function, chiropractic care reduces the systemic inflammatory burden and supports the body’s capacity to respond to medical management — including SGLT2 inhibitor therapy.
Functional medicine protocols — a cornerstone of my practice — address the root causes of metabolic dysfunction: mitochondrial insufficiency, chronic systemic inflammation, gut microbiome dysbiosis, and nutritional deficiencies. These strategies work synergistically with the pharmacology of SGLT2 inhibitors. When patients reduce systemic inflammation and optimize mitochondrial function, the cardiorenal protective mechanisms of SGLT2 inhibitors are amplified.
The collaboration between Dr. Cardenas’ internal medicine expertise and my integrative chiropractic and functional medicine approach means that patients like R.B. receive a unified, evidence-based, whole-person strategy (Jimenez, 2024).
SGLT2 inhibitors represent one of the most important advances in the management of type 2 diabetes, CKD, and heart failure in the past two decades. Their ability to reduce MACE, slow renal progression, and decrease heart failure hospitalizations — independent of A1C targets — positions them as essential tools in modern cardiorenal metabolic medicine.
At Injury Medical Clinic PA, the integration of this pharmacological knowledge within a multidisciplinary framework — anchored by the internal medicine expertise of Dr. Maria Guadalupe Cardenas, MD, and the integrative chiropractic and functional medicine practice of Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST — reflects our commitment to delivering care that is comprehensive, evidence-based, and deeply patient-centered. The future of chronic disease management is not in isolated specialties. It is in collaboration, integration, and a relentless focus on the patient standing at the intersection of multiple conditions, exactly where the opportunity for transformation is greatest.
SEO Tags: SGLT2 inhibitors, sodium-glucose cotransporter-2 inhibitors, cardiorenal protection, type 2 diabetes treatment, chronic kidney disease management, heart failure and diabetes, empagliflozin, dapagliflozin, canagliflozin, EMPA-REG OUTCOME, DAPA-CKD, CREDENCE trial, EMPA-KIDNEY, integrative chiropractic care, functional medicine El Paso, Dr. Alex Jimenez DC, Dr. Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, cardiorenal complications, RAAS activation, intraglomerular pressure, microalbuminuria, diabetic kidney disease, MACE reduction, heart failure hospitalization, ADA diabetes guidelines, AACE guidelines, SGLT2 mechanism of action, multidisciplinary diabetes care, urinary glucose excretion, euglycemic DKA, ketogenic diet SGLT2, diabetes comorbidities, osmotic diuresis, cardiovascular risk reduction, eGFR and SGLT2, DALY chronic kidney disease, global burden of heart failure, integrative medicine El Paso Texas, GLP-1 receptor agonists, continuous glucose monitor, patient education, A1C, holistic healthcare
General Disclaimer, Licenses and Board Certifications *
Professional Scope of Practice *
The information herein on "SGLT2 Inhibitors for Heart Health & Cardio-Renal Benefits" is not intended to replace a one-on-one relationship with a qualified health care professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional.
Blog Information & Scope Discussions
Welcome to El Paso's Premier Wellness and Injury Care Clinic & Wellness Blog, where Dr. Alex Jimenez, DC, FNP-C, a Multi-State board-certified Family Practice Nurse Practitioner (FNP-BC) and Chiropractor (DC), presents insights on how our multidisciplinary team is dedicated to holistic healing and personalized care. Our practice aligns with evidence-based treatment protocols inspired by integrative medicine principles, similar to those on this site and on our family practice-based chiromed.com site, focusing on naturally restoring health for patients of all ages.
Our areas of multidisciplinary practice include Wellness & Nutrition, Chronic Pain, Personal Injury, Auto Accident Care, Work Injuries, Back Injury, Low Back Pain, Neck Pain, Migraine Headaches, Sports Injuries, Severe Sciatica, Scoliosis, Complex Herniated Discs, Fibromyalgia, Chronic Pain, Complex Injuries, Stress Management, Functional Medicine Treatments, and in-scope care protocols.
Our information scope is multidisciplinary, focusing on musculoskeletal and physical medicine; wellness; contributing etiological viscerosomatic disturbances within clinical presentations; associated somato-visceral reflex clinical dynamics; subluxation complexes; sensitive health issues; and functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from various disciplines. Each specialist is governed by their professional scope of practice and licensure jurisdiction. We use functional health & wellness protocols to treat and support care for musculoskeletal injuries or disorders.
Our videos, posts, topics, and insights address clinical matters and issues that directly or indirectly relate to our clinical scope of practice.
Our office has made a reasonable effort to provide supportive citations and has identified relevant research studies that support our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We understand that we cover matters that require an additional explanation of how they may assist in a particular care plan or treatment protocol; therefore, to discuss the subject matter above further, please feel free to ask Dr. Alex Jimenez, DC, APRN, FNP-BC, or contact us at 915-850-0900.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-state Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
Colorado License #: C-APN.0105610-C-NP, Verified: C-APN.0105610-C-NP
New York License #: N25929, Verified N25929
License Verification Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
(Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director
Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified: Internal Medicine)
(Licensed Medical Doctor)
Medical Director, Clinical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933
Licenses and Board Certifications:
MD: Medical Doctor
DC: Doctor of Chiropractic
APRNP: Advanced Practice Registered Nurse
FNP-BC: Family Practice Specialization (Multi-State Board Certified)
RN: Registered Nurse (Multi-State Compact License)
CFMP: Certified Functional Medicine Provider
MSN-FNP: Master of Science in Family Practice Medicine
MSACP: Master of Science in Advanced Clinical Practice
IFMCP: Institute of Functional Medicine
CCST: Certified Chiropractic Spinal Trauma
ATN: Advanced Translational Neutrogenomics
Memberships & Associations:
TCA: Texas Chiropractic Association: Member ID: 104311
AANP: American Association of Nurse Practitioners: Member ID: 2198960
ANA: American Nurse Association: Member ID: 06458222 (District TX01)
TNA: Texas Nurse Association: Member ID: 06458222
NPI: 1205907805
| Primary Taxonomy | Selected Taxonomy | State | License Number |
|---|---|---|---|
| No | 111N00000X - Chiropractor | NM | DC2182 |
| Yes | 111N00000X - Chiropractor | TX | DC5807 |
| Yes | 363LF0000X - Nurse Practitioner - Family | TX | 1191402 |
| Yes | 363LF0000X - Nurse Practitioner - Family | FL | 11043890 |
| Yes | 363LF0000X - Nurse Practitioner - Family | CO | C-APN.0105610-C-NP |
| Yes | 363LF0000X - Nurse Practitioner - Family | NY | N25929 |
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
(Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director
Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified: Internal Medicine)*
(Licensed Medical Doctor)*
Medical Director, Clinical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933